209 related articles for article (PubMed ID: 28333404)
21. Papillary and sclerosing lesions of the breast detected and biopsied by MRI: Clinical management, upgrade rate, and association with apocrine metaplasia.
Ring NY; diFlorio-Alexander RM; Bond JS; Rosenkranz KM; Cervantes E; Sohn JH; Marotti JD
Breast J; 2019 May; 25(3):393-400. PubMed ID: 30945398
[TBL] [Abstract][Full Text] [Related]
22. Grouped Amorphous Calcifications at Mammography: Frequently Atypical but Rarely Associated with Aggressive Malignancy.
Oligane HC; Berg WA; Bandos AI; Chen SS; Sohrabi S; Anello M; Zuley ML
Radiology; 2018 Sep; 288(3):671-679. PubMed ID: 29916773
[TBL] [Abstract][Full Text] [Related]
23. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
24. Bracketing wires for preoperative breast needle localization.
Liberman L; Kaplan J; Van Zee KJ; Morris EA; LaTrenta LR; Abramson AF; Dershaw DD
AJR Am J Roentgenol; 2001 Sep; 177(3):565-72. PubMed ID: 11517048
[TBL] [Abstract][Full Text] [Related]
25. Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.
Asirvatham JR; Falcone MM; Kleer CG
Arch Pathol Lab Med; 2016 Oct; 140(10):1045-51. PubMed ID: 27684975
[TBL] [Abstract][Full Text] [Related]
26. Frequency, upgrade rates, and characteristics of high-risk lesions initially identified with breast MRI.
Strigel RM; Eby PR; Demartini WB; Gutierrez RL; Allison KH; Peacock S; Lehman CD
AJR Am J Roentgenol; 2010 Sep; 195(3):792-8. PubMed ID: 20729462
[TBL] [Abstract][Full Text] [Related]
27. Underestimation of breast cancer with II-gauge vacuum suction biopsy.
Philpotts LE; Lee CH; Horvath LJ; Lange RC; Carter D; Tocino I
AJR Am J Roentgenol; 2000 Oct; 175(4):1047-50. PubMed ID: 11000162
[TBL] [Abstract][Full Text] [Related]
28. Lobular carcinoma in situ diagnosed by core needle biopsy: when should it be excised?
Middleton LP; Grant S; Stephens T; Stelling CB; Sneige N; Sahin AA
Mod Pathol; 2003 Feb; 16(2):120-9. PubMed ID: 12591964
[TBL] [Abstract][Full Text] [Related]
29. Cancerization of small ectatic ducts of the breast by ductal carcinoma in situ cells with apocrine snouts: a lesion associated with tubular carcinoma.
Goldstein NS; O'Malley BA
Am J Clin Pathol; 1997 May; 107(5):561-6. PubMed ID: 9128269
[TBL] [Abstract][Full Text] [Related]
30. Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ.
Grimm LJ; Ghate SV; Hwang ES; Soo MS
Acad Radiol; 2017 Nov; 24(11):1364-1371. PubMed ID: 28705686
[TBL] [Abstract][Full Text] [Related]
31. The radiological excision of high risk and malignant lesions using the INTACT breast lesion excision system. A case series with an imaging follow up of at least 5 years.
Allen SD; Osin P; Nerurkar A
Eur J Surg Oncol; 2014 Jul; 40(7):824-9. PubMed ID: 24742589
[TBL] [Abstract][Full Text] [Related]
32. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
33. Is the upgrade rate of atypical ductal hyperplasia diagnosed by core needle biopsy of calcifications different for digital and film-screen mammography?
McLaughlin CT; Neal CH; Helvie MA
AJR Am J Roentgenol; 2014 Oct; 203(4):917-22. PubMed ID: 25247961
[TBL] [Abstract][Full Text] [Related]
34. CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast.
Kővári B; Báthori Á; Cserni G
Pathobiology; 2015; 82(6):259-63. PubMed ID: 26562027
[TBL] [Abstract][Full Text] [Related]
35. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Pilewskie M; Stempel M; Rosenfeld H; Eaton A; Van Zee KJ; Morrow M
Ann Surg Oncol; 2016 Oct; 23(11):3487-3493. PubMed ID: 27172775
[TBL] [Abstract][Full Text] [Related]
36. Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy.
Ko E; Han W; Lee JW; Cho J; Kim EK; Jung SY; Kang MJ; Moon WK; Park IA; Kim SW; Kim KS; Lee ES; Min KH; Kim SW; Noh DY
Breast Cancer Res Treat; 2008 Nov; 112(1):189-95. PubMed ID: 18060577
[TBL] [Abstract][Full Text] [Related]
37. Significance of flat epithelial atypia on mammotome core needle biopsy: Should it be excised?
Kunju LP; Kleer CG
Hum Pathol; 2007 Jan; 38(1):35-41. PubMed ID: 17095049
[TBL] [Abstract][Full Text] [Related]
38. Cytologic findings of atypical adenosis of the breast. A case report.
Kaufman D; Sanchez M; Mizrachy B; Jaffer S
Acta Cytol; 2002; 46(2):369-72. PubMed ID: 11917587
[TBL] [Abstract][Full Text] [Related]
39. Core Breast Biopsies Showing Lobular Carcinoma In Situ Should Be Excised and Surveillance Is Reasonable for Atypical Lobular Hyperplasia.
Sen LQ; Berg WA; Hooley RJ; Carter GJ; Desouki MM; Sumkin JH
AJR Am J Roentgenol; 2016 Nov; 207(5):1132-1145. PubMed ID: 27532153
[TBL] [Abstract][Full Text] [Related]
40. The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: a study of 100 cases from four academic institutions.
Khoury T; Li Z; Sanati S; Desouki MM; Chen X; Wang D; Liu S; Karabakhtsian R; Kumar P; Reig B
Histopathology; 2016 Apr; 68(5):713-21. PubMed ID: 26291517
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
